Sun Pharmaceutical Industries Limited (BOM:524715)
India
· Delayed Price · Currency is INR | Market Cap | 4.19T |
| Revenue (ttm) | 568.09B |
| Net Income (ttm) | 109.15B |
| Shares Out | n/a |
| EPS (ttm) | 45.45 |
| PE Ratio | 38.41 |
| Forward PE | 31.79 |
| Dividend | 16.50 (0.95%) |
| Ex-Dividend Date | Feb 5, 2026 |
| Volume | 214,224 |
| Average Volume | 200,694 |
| Open | 1,733.55 |
| Previous Close | 1,733.80 |
| Day's Range | 1,715.05 - 1,763.80 |
| 52-Week Range | 1,547.25 - 1,850.95 |
| Beta | n/a |
| RSI | 55.90 |
| Earnings Date | May 22, 2026 |
About BOM:524715
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, urology, dermatology, respira... [Read more]
Financial Performance
In fiscal year 2025, BOM:524715's revenue was 525.78 billion, an increase of 8.42% compared to the previous year's 484.97 billion. Earnings were 109.29 billion, an increase of 14.12%.
Financial StatementsNews
How Sun Pharma’s U.S. buy could spur other Indian pharma firms' global expansion
Kunal Dhamesha, Senior Analyst at Macquarie Capital, says Sun Pharma’s U.S. acquisition could encourage its peers to look beyond generics and pursue M&As in specialty and patented medicines, though ap...
Sun Pharma sees Rs 24 crore block deal as 139,060 shares change hands
Shares of Sun Pharmaceutical Industries remained largely flat in early trade on Tuesday, April 28, even as a block deal was executed in the stock. The shares were trading around…
Sun Pharma buys US-based Organon for $12 billion in biggest-ever overseas pharma deal
India's largest pharma company, Sun Pharma, has made its biggest overseas acquisition, buying Organon & Co for $11.8 billion. This deal significantly expands Sun Pharma's global presence and product r...
Gujarat’Sun Pharma to acquire Organon in $11.8bn all-cash deal
Ahmedabad: Homegrown pharma major Sun Pharmaceutical Industries Ltd on Monday announced it has signed a definitive agreement to acquire US-based Organ.
Stock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash Deal
Today, April 27, 2026, a jumbo all-cash buyout and merger-arb dynamics put Organon in focus.
Sun Pharmaceutical (SUNPHARMA) Acquires Oganon for $11.75 Billion in Cash
Sun Pharmaceutical (SUNPHARMA) Acquires Oganon for $11.75 Billion in Cash
Indian Shares Climb On Firm Global Cues; Sun Pharma Shares Rally 7%
(RTTNews) - Indian shares rose notably on Monday, with mostly positive cues from global markets helping underpin sentiment.
Nifty 50 top gainers today, April 27: Sun Pharma, Jio Financial Services, Wipro, Reliance Industries and more
The benchmark indices ended higher on April 27, with the Nifty 50 closing at 24,092.70, up 194.75 points or 0.81%. The BSE Sensex gained 639.42 points or 0.83% to settle…
Why Is Organon Stock Skyrocketing Monday?
Sun Pharma to acquire Organon in an all-cash deal valued at $11.75 billion. OGN shares rise on the acquisition news. ... Full story available on Benzinga.com
Sun Pharmaceutical To Buy Organon For $11.75 Bln
(RTTNews) - Sun Pharmaceutical Industries Limited (SUNPHARMA, 524715), a major Indian pharma company, said on Monday that it has inked a deal to buy Organon & Co.(OGN) for $14 per share in cash with a...
Sun Pharma Acquires Organon & Co for $11.75 Billion
Sun Pharma Acquires Organon & Co for $11.75 Billion
Organon To Be Acquired By Sun Pharma In $11.75B Deal, OGN Stock Spikes Nearly 17% On Robinhood 24-Hour Market
Organon & Co. (NYSE: OGN) said on Sunday it signed a definitive agreement to be acquired by Sun Pharmaceutical Industries in an all-cash deal valued at $11.75 billion. According to the terms of the a...
Sun Pharma to acquire US-based Organon in $11.75bn deal
Indian pharmaceutical giant Sun Pharma is set to acquire US-based Organon & Co. for $11.75 billion in an all-cash deal. This landmark acquisition, one of India's largest overseas ventures, will propel...
Pharma sector stocks surge today, April 27: Sun Pharma jumps 6.62%, Aarti Drugs up 3.50%, Alembic Pharma rises 2.86%
Indian pharmaceutical stocks broadly advanced on Monday morning, with the Nifty Pharma Index rising 2.4% to 23,131.5. The S&P BSE Healthcare Index climbed 1.47% to 44,259.96, outperforming the broader...
Sun Pharma shares price jumps over 5% after $11.75 billion Organon acquisition deal announcement
Shares of Sun Pharmaceutical Industries Ltd jumped more than 5% in early trade after the company announced a major global acquisition deal involving Organon & Co. The transaction marks one…
Sun Pharma shares register its biggest intraday rally since 2021
Shares of Sun Pharmaceutical Industries Ltd jumped more than 8% in early trade to register its biggest intraday rally since 2021 after the company announced a major global acquisition deal…
Sun Pharma to acquire US-listed Organon for $11.75 billion in one of India’s largest pharma deals
Sun Pharmaceutical Industries Ltd has agreed to acquire US-based Organon & Co for $11.75 billion in an all-cash deal. This significant outbound acquisition is expected to close in early 2027, strength...
Sun Pharmaceutical Industries Transcript: M&A announcement
The acquisition will create a top 25 global pharma company with a strong presence in women's health, biosimilars, and innovative medicines, leveraging Organon's global footprint and Sun's execution capabilities. The $11.75B deal is expected to deliver $350M in cost synergies over 2-4 years and be EPS accretive from year one.
Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal
To fuel its global ambitions, Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion.
Sun Pharmaceutical Industries to Acquire Organon & Co. for $11.75 Billion
Sun Pharmaceutical Industries to Acquire Organon & Co. for $11.75 Billion
Sun Pharmaceutical to Acquire Organon (OGN) for $14 per Share
Sun Pharmaceutical to Acquire Organon (OGN) for $14 per Share
Sun Pharmaceutical to Acquire Ognon for $14 Per Share, Valuing Deal at $11.75 Billion
Sun Pharmaceutical to Acquire Ognon for $14 Per Share, Valuing Deal at $11.75 Billion
Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma
Organon (OGN) Shares Surge on $13B Acquisition Bid from Sun Pharma
Organon (OGN) Shares Surge on $13B Acquisition Bid from Sun Pharma
Sun Pharmaceutical Plans $13B Bid for Organon (OGN)
Sun Pharmaceutical Plans $13B Bid for Organon (OGN)